Top Qs
Timeline
Chat
Perspective
Lexatumumab
Monoclonal antibody From Wikipedia, the free encyclopedia
Remove ads
Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2), intended for the treatment of cancer.[1][2]
HGS-ETR2 antibodies were generated by Human Genome Sciences through a collaboration with Cambridge Antibody Technology.[3]
Development was discontinued in 2015.[4]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads